Tenax Therapeutics, Inc.TENXNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank41
3Y CAGR-61.2%
5Y CAGR+7.5%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
-61.2%/yr
Quarterly compound
5Y CAGR
+7.5%/yr
Recent deceleration
Percentile
P41
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.50% |
| Q3 2025 | -48.15% |
| Q2 2025 | 3.57% |
| Q1 2025 | -55.56% |
| Q4 2024 | 5.26% |
| Q3 2024 | 89.62% |
| Q2 2024 | 41.35% |
| Q1 2024 | 71.14% |
| Q4 2023 | -63.54% |
| Q3 2023 | -65.25% |
| Q2 2023 | 66.94% |
| Q1 2023 | 88.11% |
| Q4 2022 | 42.69% |
| Q3 2022 | 2.20% |
| Q2 2022 | -5.09% |
| Q1 2022 | 19.27% |
| Q4 2021 | 11.25% |
| Q3 2021 | -51.15% |
| Q2 2021 | 93.92% |
| Q1 2021 | -827.27% |
| Q4 2020 | 1.74% |
| Q3 2020 | 21.74% |
| Q2 2020 | 39.47% |
| Q1 2020 | -7251.87% |
| Q4 2019 | 98.43% |
| Q3 2019 | -17.86% |
| Q2 2019 | 15.15% |
| Q1 2019 | 78.35% |
| Q4 2018 | -45.76% |
| Q3 2018 | 18.83% |
| Q2 2018 | -58.60% |
| Q1 2018 | 14.70% |
| Q4 2017 | -8.88% |
| Q3 2017 | 58.67% |
| Q2 2017 | 8.84% |
| Q1 2017 | -780.62% |
| Q4 2016 | 91.34% |
| Q3 2016 | 7.92% |
| Q2 2016 | 13.44% |
| Q1 2016 | -3820703.72% |